Skip to content

Our Mission

A disease that is common, growing, and treatable if it’s diagnosed in time

We are committed to reducing the number of preventable amputations worldwide, thereby reducing the significant morbidity, mortality, and burden of Critical Limb-Threatening Ischemia (CLTI) disease in people living with Peripheral Arterial Disease (PAD).

The Scale of the Problem

A very complicated and highly devastating disease

Despite falling rates in some regions, prevalence of PAD is climbing as the global population ages and grows. Amputation remains, far too often, the default treatment option.

360 million Projected global PAD cases by 2050, a 220% rise from today, with estimates ranging 270–450 million1
236 million People currently affected worldwide under the broader lower-extremity PAD (LEPAD) definition2
11–23 million People living with CLTI globally3,4,5,6, an estimated 5–10% of all PAD patients.
50–65% CLTI patients have a type of diabetes.22

Diabetes

An estimated 589 million adults aged 20–79 are living with diabetes, representing 11.1% of the world’s population in that age group. The number is projected to rise to 853 million (about 13% of adults) by 2050.8

Amputation

10–20% of patients with CLTI ultimately require a major amputation, despite advances in limb salvage. This corresponds to an estimated 2–5 million people worldwide living with or eventually undergoing major limb amputation related to CLTI.5

Diabetes is present in approximately 50–65% of CLTI patients,22 so diabetes-related amputation statistics are often used as a surrogate. A recent global meta-analysis estimated annual diabetes-related incidence of major amputations at 94.8 per 100,000 people with diabetes, and minor amputations at 140.0 per 100,000 people with diabetes.7

Population-based studies report overall major lower-extremity amputation rates ranging from 3.6 to 68.4 per 100,000 persons annually, while approximately 22% of untreated CLTI patients undergo major amputation within one year. Major amputation rates are declining in many high-income countries but continue to rise in many low- and middle-income countries.5

Without timely revascularization, limb amputation occurs in approximately 25%–30% of CLTI patients within one year of diagnosis.9,10

Percutaneous transluminal angioplasty and stenting represented 78% of all U.S. critical limb ischemia interventions in 2025, up from 62% five years earlier, due to shorter recovery times and lower hospital costs.5

Amputation

An Unacceptable First Option

In the United States

– The best estimate for the prevalence of PAD in the US in 2020 is 19 to 21 million and continues to be underestimated.11

– Nearly 2 million people are living with limb loss.12

– Among those living with limb loss, the main causes are vascular disease (54%), including diabetes and peripheral arterial disease, trauma (45%) and cancer (less than 2%).12

– Approximately 185,000 amputations occur every year.13

– In 2020, the direct medical costs of major amputation were $13.4 billion.14 The majority of these costs are inpatient, because the Centers for Medicare & Medicaid Services pay almost 80% of the amputation bill.15

– African-American patients are up to four times more likely to undergo an amputation than white patients.16

– Nearly half of people who lose a limb to vascular disease die within five years, a higher rate than for breast, colon, or prostate cancer.17

– Up to 55% of people with diabetes who lose one leg will lose the second within 2–3 years.18

– An angiogram reduces the odds of undergoing amputation by 90%.19 Despite this, 54% to 67% of CLI patients have no angiogram performed prior to major amputation.20,21 Consequently, requiring an angiogram prior to major amputation and denying reimbursement if one is not performed should significantly reduce amputations.

Our People

Leadership Team

George Quinoy

George Quinoy

President and CEO

Mr. Quinoy is a seasoned C-suite executive with a proven track record of building and scaling commercial enterprises in the medical device and vascular space.

Throughout his career, George has played a pivotal role in driving rapid and sustained expansion for renowned companies, including AVE, Medtronic, ACS/Guidant, Volcano Corp., and most recently, Provisio Medical.

He has demonstrated expertise in commercialization, strategic planning, forecasting, and product launches, building world-class sales organizations that lead to successful acquisitions by industry leaders. His leadership at Volcano Corp. helped grow the company from startup to over $400 million in annual sales, culminating in the company’s acquisition by Royal Philips in 2015.

George holds a Bachelor of Science degree in Public Relations from the University of Florida and continues to be a key influence in vascular innovation and commercialization.

Kathleen Dennis

Kathleen Dennis

Senior VP of Operations

Ms. Dennis joined Micro Medical Solutions in June 2023, bringing with her over 25 years of proven senior leadership experience assisting emerging medical device and pharmaceutical companies with strategy, implementation of business infrastructure and building key supply chain partnerships.

Her expertise spans product development, program management, quality systems, regulatory compliance and manufacturing operations and has led efforts to achieve CE mark, NDA/PMA approval and regulatory compliance for successful FDA inspections. She held several management roles of increasing responsibility at Boston Scientific, Aeris Therapeutics and Thermo Cardiosystems.

Kathleen earned an MBA from Babson College and a B.S. in Mechanical Engineering from Northeastern University.

Rita Jacob

Rita Jacob

VP of Clinical Administration

Ms. Jacob joined Micro Medical Solutions in 2022. She brings a history of collaborating with medical device company executives and key stakeholders to deliver results in FDA regulated clinical research, medical training and scientific marketing.

After spending nearly a decade in cardiovascular intensive care nursing, Rita evolved her passion for exceptional patient care to delivering novel high-risk medical devices into physicians’ hands for over 25 years. Her career has included Fortune 100 and 500 companies as well as many start-up companies. Team focus, results orientation and ethical behavior is her ethos.

Ms. Jacob has many career firsts that include the first FDA approved aortic stent graft, first interventional venous thrombus protection device, first US industry data registries with the Society of Vascular Surgery and the American Venous Forum and the first to obtain FDA approval to change a PMA clinical study strategy from RCT to TPG. For these Class III device projects Rita developed study protocols that met FDA PMA requirements, recruited qualified study investigators/sites, managed the studies in compliance with Good Clinical Practices (GCP) and prepared final statistical analyses and PMA study reports. She has established and completed publication strategies resulting in physician authored manuscript acceptance in Tier I and II peer reviewed journals.

David Goodman

David Goodman

VP of Global Marketing

Mr. Goodman joined Micro Medical Solutions in April 2026. He has over 30 years of medical device industry experience in multiple roles. A seasoned medical device executive with a history of commercialization of novel medical device technologies.

Mr. Goodman has had roles in Marketing, Market Development, Training & Education, Sales, QA and Manufacturing Operations. He has worked for companies such as Provisio Medical, Penumbra, Volcano/Philips, Trivascular (now Rhevera Medical/Endologix), Medtronic, Intuitive Surgical, Ethicon Endo-Surgery and Ethicon, Inc. (both Johnson & Johnson companies).

Mr. Goodman holds a B.S. in Applied Sciences in Engineering from Rutgers University.

Peg Thornton

Peg Thornton

VP of Strategic Initiatives

Ms. Thornton brings extensive experience in medical device commercialization, strategic business development, and corporate finance.

Ms. Thornton has played a role in bringing innovative medical technologies to market through sales and commercial leadership positions with industry pioneers including Advanced Cardiovascular Systems/AVE, Medtronic, ev3, Acclarent, and MMS. Her experience spans both emerging medical technology companies and established industry leaders, providing a strong understanding of the commercial, financial, and strategic considerations involved in introducing novel technologies.

Ms. Thornton began her career with USCI, a division of C.R. Bard, before joining Ernst & Young’s Corporate Finance Group, where she supported business development activities across mergers and acquisitions, business valuation, and litigation support practices. This foundation in corporate finance, combined with her medical device industry experience, provides a perspective on business strategy, strategic partnerships, and long-term value creation.

Ms. Thornton holds an MBA in Finance from Villanova University.

Mike Hogan

Mike Hogan

Director of Investor Relations

Michael Hogan is an experienced entrepreneur, investor-relations executive, and strategic business advisor who has spent his career helping emerging and growth-stage companies raise capital, develop strategic relationships, and communicate their value to investors, partners, and other key stakeholders.

His experience spans medical devices, artificial intelligence, technology, media, and other entrepreneurial ventures. Throughout his career, Michael has worked closely with founders, executive leadership teams, and boards of directors on capital formation, investor communications, business development, strategic partnerships, and commercialization initiatives.

Known for his relationship-driven approach and ability to translate complex technologies into clear and compelling business opportunities, Michael brings together the right people, resources, and strategies to help companies overcome challenges and achieve sustainable growth.

Ray Brown

Ray Brown

Controller

Ray is a seasoned financial executive and Certified Public Accountant (CPA) with over 40 years of accounting and financial management experience, including 25+ years as a licensed CPA.

As Controller at Micro Medical Solutions (MMS), Ray provides the critical financial leadership, continuity, and fiscal management necessary to support the company’s ongoing growth and strategic initiatives.

With more than two decades of experience serving as Controller for small and mid-sized companies, Ray brings deep expertise in optimizing financial reporting, scaling accounting operations, and strengthening internal controls. He began his professional accounting career spending two years with Deloitte & Touche, one of the world’s leading public accounting firms, building a rigorous foundation in corporate finance.

A veteran of the United States Air Force, Ray infuses the organization with a lifelong foundation of discipline, integrity, and operational leadership.

Pete Campanella

Pete Campanella

Area VP of Sales

Mr. Campanella is a seasoned medical device executive with 38 years of experience leading high-growth companies, accelerating revenue, and expanding markets. From frontline sales to vice president roles, he has built and scaled startups, delivered sustained business growth, and led multiple successful exits.

Dario Duany, Jr.

Dario Duany, Jr.

Area VP of Sales

Dario Duany Jr. brings 35 years of proven success in building businesses and launching breakthrough medical devices, from early-stage startups through acquisition by leading global medical technology companies.

His extensive experience spans the full vascular landscape, including coronary, neurovascular, aortic, thoracic aneurysm repair, and peripheral vascular therapies. Throughout his career, Dario has contributed to businesses acquired by industry leaders such as Guidant, Medtronic, Boston Scientific, and Terumo Aortic. A consistent top performer and proven leader, he has advanced from Territory Manager to Division Manager and Director of Sales, combining strategic vision, commercial execution, and deep industry expertise to drive growth and market success.

Board of Directors

George Quinoy

George Quinoy

President and CEO

A C-suite executive with a track record of building and scaling commercial enterprises in the medical device and vascular space, most recently at Provisio Medical.

George Quinoy

President and CEO

George Quinoy, President and CEO is a seasoned C-suite executive with a proven track record of building and scaling commercial enterprises in the medical device and vascular space. Throughout his career, George has played a pivotal role in driving rapid and sustained expansion for renowned companies, including AVE, Medtronic, ACS/Guidant, Volcano Corp., and most recently, Provisio Medical.

He has demonstrated expertise in commercialization, strategic planning, forecasting, and product launches, building world-class sales organizations that lead to successful acquisitions by industry leaders. His leadership at Volcano Corp. helped grow the company from startup to over $400 million in annual sales, culminating in the company’s acquisition by Royal Philips in 2015.

George holds a Bachelor of Science degree in Public Relations from the University of Florida and continues to be a key influence in vascular innovation and commercialization.
John Dahldorf

John Dahldorf

Chief Financial Officer

More than 25 years leading finance and accounting functions in public and private healthcare companies, among them Volcano Corporation and Acutus Medical.

John Dahldorf

Chief Financial Officer

John Dahldorf joined Q’apel Medical, Inc. on March 31, 2025 as Chief Financial Officer. He previously was the CFO of Digirad Corporation, Volcano Corporation, Acutus Medical, SCN Bestco and Adagio Medical Holdings.

He has more than 25 years of experience leading finance and accounting functions in public and private healthcare companies and currently serves on the Board of Directors of Hyperfine, Inc. John holds a Bachelors degree in Finance and a MBA from Western Illinois University.
Vince Burgess

Vince Burgess

Former President and CEO of Acutus Medical and a Venture Partner at OrbiMed Advisors, previously on the founding executive team at Volcano Corporation.

Vince Burgess

Vince Burgess has been a member of our Board since November 2025. Mr. Burgess recently served as President, Chief Executive Officer and member of the board of directors of Acutus Medical, Inc., a medical device company, from October 2017 until May 2022, and previously served as a Venture Partner with OrbiMed Advisors, LLC, a healthcare investment firm, from September 2011 until May 2020.

Previously, Mr. Burgess was a member of the initial executive team at Volcano Corporation, where he served as President of Advanced Imaging Systems. He also led marketing and business development at Volcano from 2002 to 2010.

He currently serves as a member of the board of directors of Tela Bio, Inc. and has previously served on the boards of Bolt Medical, NeuroPace, Inc., Sonendo Inc., Keystone Heart, Inc., Vessix Vascular, Cryterion Medical and CardiAQ, Inc. He earned his Bachelor of Science degree in Business Administration from the University of Southern California and his Masters of Business Administration from the University of California, Los Angeles.
John Fletcher

John Fletcher

Founder of Fletcher Spaght and its Managing Director Emeritus, and chairman of the boards of ClearPoint Neuro, Koru Medical and Metabolon.

John Fletcher

John Fletcher founded Fletcher Spaght in 1983 and remains active as the Managing Director Emeritus. FSI has been unique in applying analytic rigor coupled with operational expertise to a broad range of clients, portfolio companies and the investment community. John has particular interests in devices, specifically in cardiology, cardiac surgery, and orthopedics, as well as in biopharma and healthcare IT. Prior to founding Fletcher Spaght, John was a Senior Manager at The Boston Consulting Group, advising a broad range of companies in healthcare and high technology industries.

John currently serves as the Chairman of the Board of Directors for ClearPoint Neuro, Koru Medical, and Metabolon. Previously, he served as Chairman of Spectranetics during its turnaround and subsequent sale to Philips N.V. For this work as well as his work on the board of Axcelis Corporation, he was selected as Director of the Year by the National Association of Corporate Directors. He is Chairman Emeritus of the Corporate Collaboration Council at the Thayer School of Engineering/Tuck School of Business at Dartmouth College and serves on the Board of Advisors of Beth Israel Deaconess Medical Center and the Whitehead Institute at MIT.

John received his MBA from Southern Illinois University, a Master’s degree in International Finance from Central Michigan University, and a BBA in Marketing from George Washington University. He was an Instructor for courses in international business and a PhD Candidate at the Wharton School of the University of Pennsylvania. He served as a Captain and jet pilot in the U.S. Air Force and continues to be active in aviation.
Dr. Ronald Solar

Dr. Ronald Solar

Designing and developing medical devices for over 45 years, holder of more than 68 US patents and co-founder of Y Med, X Technologies, Pameda/Occam and Versaflex.

Dr. Ronald Solar

Dr. Ronald Solar received his Ph.D. in Biomaterials and Materials Science from the University of Pennsylvania, and has been designing and developing medical devices for over 45 years. He co-founded several successful medical device companies, including Y Med (sold to CR Bard), X Technologies (sold to Guidant), Pameda/Occam (sold to Cordis) and Versaflex (sold to Medtronic). Dr. Solar also played key leadership and development roles for Edwards, Advanced Cardiovascular Systems, SciMed and Medtronic, and he currently holds over 68 US patents.

In 1989, Dr. Solar was recognized by President George H. W. Bush as one of the Ten Outstanding Young Americans, and Junior Chamber International (JCI) selected him as one of the Ten Outstanding Young People of the World for his contributions in medical innovation.

He is a Fellow of the European Society of Cardiology and his current research interests include peripheral, neuro and cardiovascular disease, vascular injury, local drug delivery, and selective hypothermia to treat stroke and other cerebral ischemic disorders.

Medical Advisory Board

Robert Beasley, MS, MD

Robert Beasley, MS, MD

Director of Vascular/Interventional
Radiology and Vein Treatment Center
Mt. Sinai Medical Center
Miami Beach, FL, United States
Marco Manzi, MD

Marco Manzi, MD

Director of Interventional Radiology
Policlinico Abano Terme
Abano Terme, Italy
Andrej Schmidt, MD

Andrej Schmidt, MD

University Hospital of Leipzig
Leipzig, Germany
Eric A. Secemsky, MD, MSc

Eric A. Secemsky, MD, MSc

Beth Israel Deaconess Medical Center (BIDMC)
Boston, MA, United States
Bob Tahara, MD

Bob Tahara, MD

Meadville Medical Center
Bradford, PA, United States
Craig Walker, MD

Craig Walker, MD

Founder, President and Medical Director
Cardiovascular Institute of the South
Houma, LA, United States
Chairman
New Cardiovascular Horizons
Thomas Zeller, MD, PhD

Thomas Zeller, MD, PhD

Department of Angiology
Clinic Cardiology-Angiology II
University Heart Center
Freiburg-Bad Krozingen, Germany
Lorenzo Patrone, MD

Lorenzo Patrone, MD

Vascular and Interventional Radiology Consultant
ASL Toscana Centro – Ospedale San Giovanni di Dio
Florence, Tuscany, Italy

References:

  1. Deng L, Du C, Liu L, Wang Y, Gu H, Armstrong DG, Mills JL, Hochlenert D, Deng H, Ran J, Chen Y, Jiang X, Ma Y, Chen Q, Deng W; “Flow and Toe” Research Team (FORT). Forecasting the Global Burden of Peripheral Artery Disease from 2021 to 2050: A Population-Based Study. Research (Wash D C). 2025 Jul 1;8:0702. doi:10.34133/research.0702.
  2. Zhang G, Liu X, Li J, Zhao Y, Yuan Z, Chen Y, Zhang S, Chang M, Jin L, Tao C, Tang R, Lan Z. Global, regional, and national burdens of lower extremity peripheral arterial disease from 1990 to 2021 and projections to 2050: global burden of disease study 2021. Front Cardiovasc Med. 2025;12:1592322. doi:10.3389/fcvm.2025.1592322.
  3. Fowkes FG, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010. Lancet. 2013.
  4. Song P, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease, 2000–2019. The Lancet Global Health. 2024.
  5. Conte MS, Bradbury AW, Kolh P, et al. Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Eur J Vasc Endovasc Surg. 2019;58(1 Suppl):S1-S109.e33. doi:10.1016/j.ejvs.2019.05.006. Published simultaneously in J Vasc Surg. 2019.
  6. Teraa M, Conte MS, Moll FL, Verhaar MC. Critical Limb Ischemia: Current Trends and Future Directions. Journal of the American Heart Association. 2016.
  7. Ezzatvar Y, García-Hermoso A. Global estimates of diabetes-related amputations incidence in 2010–2020: A systematic review and meta-analysis. Diabetes Research and Clinical Practice. 2023;195:110194. doi:10.1016/j.diabres.2022.110194.
  8. International Diabetes Federation. Diabetes prevalence and projections. NCBI Bookshelf NBK618744. https://www.ncbi.nlm.nih.gov/books/NBK618744/
  9. N Engl J Med. 2022;387:2305-2316. doi:10.1056/NEJMoa2207899.
  10. Gooneratne T, Cassim R, Wijeyaratne M. Major Lower Limb Amputation for Chronic Limb-Threatening Ischemia Is Associated with Poor Long-Term Survival: 4-Year Follow-Up of a Single-Center Experience. Ann Vasc Dis. 2024;17(3):234-240. doi:10.3400/avd.oa.23-00078.
  11. Yost ML. Critical limb ischemia volume I, U.S. epidemiology, 2016 supplement. The Sage Group. 2016.
  12. Ziegler-Graham K, MacKenzie EJ, Ephraim PL, Travison TG, Brookmeyer R. Estimating the Prevalence of Limb Loss in the United States: 2005 to 2050. Archives of Physical Medicine and Rehabilitation. 2008;89(3):422-9.
  13. Owings M, Kozak LJ, National Center for Health Statistics. Ambulatory and Inpatient Procedures in the United States, 1996. Hyattsville, MD: U.S. Dept. of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 1998.
  14. Yost ML. The cost of critical limb ischemia (CLI). Why is the disease so costly? The Sage Group. 2019.
  15. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project: HCUP query: analysis of ICD-10 procedure codes for major amputation. Accessed June 2020. http://www.hcup.ahrq.gov/
  16. Fisher ES, Goodman DC, Chandra A. Disparities in Health and Health Care among Medicare Beneficiaries: A Brief Report of the Dartmouth Atlas Project. Robert Wood Johnson Foundation. 2008.
  17. Robbins JM, Strauss G, Aron D, Long J, Kuba J, Kaplan Y. Mortality Rates and Diabetic Foot Ulcers. Journal of the American Podiatric Medical Association. 2008;98(6):489-93.
  18. Pandian G, Hamid F, Hammond M. Rehabilitation of the Patient with Peripheral Vascular Disease and Diabetic Foot Problems. In: DeLisa JA, Gans BM, editors. Philadelphia: Lippincott-Raven; 1998.
  19. Henry AJ, Hevelone ND, Belkin M, Nguyen LL. Socioeconomic and hospital-related predictors of amputation for critical limb ischemia. J Vasc Surg. 2011;53:330-339.e1. doi:10.1016/j.jvs.2010.08.077.
  20. Allie DE, Hebert CJ, Lirtzman MD, et al. Critical limb ischemia: a global epidemic. A critical analysis of current treatment unmasks the clinical and economic costs of CLI. EuroIntervention. 2005;1:75-84.
  21. Goodney PP, Travis LL, Nallamothu BK, et al. Variation in the use of lower extremity vascular procedures for critical limb ischemia. Circ Cardiovasc Qual Outcomes. 2012;5:94-102. doi:10.1161/CIRCOUTCOMES.111.962233.
  22. Yost ML. The cost of critical limb ischemia (CLI). Why is the disease so costly? Beaufort (SC): THE SAGE GROUP; 2019.